Maze Therapeutics (NASDAQ:MAZE – Free Report) had its price target increased by Wedbush from $48.00 to $49.00 in a research report report published on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock.
Several other equities analysts also recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Citigroup initiated coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research note on Thursday, September 24th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $65.50.
Get Our Latest Stock Report on Maze Therapeutics
Maze Therapeutics Stock Down 1.7%
Shares of MAZE stock opened at $36.09 on Tuesday. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The firm has a market capitalization of $1.97 billion, a PE ratio of -13.62 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 14.14. The stock’s 50-day simple moving average is $28.51 and its 200-day simple moving average is $31.59.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). Equities analysts expect that Maze Therapeutics will post -2.76 earnings per share for the current year.
Insider Buying and Selling at Maze Therapeutics
In other news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $723,975. The trade was a 22.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 176,849 shares of company stock valued at $4,741,878. 5.30% of the stock is owned by company insiders.
Institutional Trading of Maze Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. grew its holdings in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at about $133,502,907. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth about $101,764,000.
More Maze Therapeutics News
Investors following MAZE have been watching these news items:
- Positive Sentiment: A report on Maze’s third-quarter results highlighted progress from its HORIZON trial, a potentially supportive development for the company’s pipeline, although it also noted a wider loss. Maze Therapeutics Q3 2026: Wider Loss, But HORIZON Trial Delivers
- Neutral Sentiment: JPMorgan lowered its price target to $51 from $53 but kept an Overweight rating, signaling continued optimism while trimming its valuation outlook. JPMorgan lowers Maze Therapeutics price target
- Negative Sentiment: HC Wainwright cut its EPS estimates across 2026–2030 and several upcoming quarters, forecasting larger losses—including FY2027 EPS of ($3.15), down from ($2.60). These revisions may pressure MAZE, despite the firm retaining a Buy rating and $110 target. Maze Therapeutics analyst estimates
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.
See Also
- Five stocks we like better than Maze Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
